We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HSY:NYSEThe Hershey Company Analysis

Data as of 2026-03-10 - not real-time

$220.88

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

The Hershey Company (HSY) trades at $220.88, well above its DCF‑derived fair value of $109.67, implying a modest 4.1% upside but a substantial valuation gap. Technicals show a bullish alignment of the 20‑day (227.13), 50‑day (207.62) and 200‑day (186.38) SMAs, yet the MACD histogram is negative (-2.23) and the RSI sits at 49.8, suggesting limited momentum and potential short‑term weakness near the $214.62 support level. Volume is trending down, and the stock’s beta of 0.12 underscores its defensive, low‑volatility nature. Fundamentals reveal a solid dividend yield of 2.61% but an unsustainable payout ratio of 126%, a high PE of 50.9 (forward PE 22.5), and a debt‑to‑equity ratio of 124%, which together heighten valuation concerns.
Recent news highlights a 6% dividend increase to $1.45, a falling short‑interest to 7.28% of float, and a Zacks Rank 1 “Strong Buy” label, reinforcing investor confidence in brand strength and growth prospects. However, the combination of overvaluation, modest revenue growth (7%), and elevated leverage suggests that investors should weigh the defensive appeal against the risk of a price correction.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price approaching the $214.62 support level
  • Bearish MACD histogram despite bullish SMA alignment
  • Decreasing volume indicating waning short‑term buying pressure

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustained bullish trend across 20/50/200‑day SMAs
  • Strong brand portfolio and defensive sector positioning
  • High valuation multiples (PE 50.9, P/B 9.66) limiting upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Resilient consumer demand for confectionery and snack categories
  • Low beta (0.12) and defensive sector provide stability
  • Potential for valuation re‑rating if price aligns closer to DCF fair value

Key Metrics & Analysis

Financial Health

Revenue Growth7.00%
Profit Margin7.55%
P/E Ratio50.9
ROE18.89%
ROA6.89%
Debt/Equity123.76
P/B Ratio9.7
Op. Cash Flow$2.3B
Free Cash Flow$1.4B

Technical Analysis

TrendBullish
RSI49.8
Support$214.62
Resistance$239.48
MA 20$227.13
MA 50$207.62
MA 200$186.38
MACDBearish
VolumeDecreasing
Fear & Greed Index80.45

Valuation

Fair Value$109.67
Target Price$230.00
Upside/Downside4.13%
GradeOvervalued
TypeValue
Dividend Yield2.61%

Risk Assessment

Beta0.12
Volatility33.31%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.